MediFormatica’s Post

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

#fundingalert 💼Company: HEPHAISTOS-Pharma 💰Funding: €4.5 Million ⚡Round: Seed 👥Investors: Elaia, xista science ventures, the Fondation Fournier-Majoie and Noshaq. HEPHAISTOS-Pharma is a preclinical biotech company developing the next generation of #immunostimulants against cancer, revolutionizing immune stimulation targeting innate immunity with a unique technology for intravenous administration, opening the way to metastatic and hard-to-treat indications. This seed round will mainly #finance the industrialization of drug production and regulatory toxicity studies to file for the CTA in Europe. HEPHAISTOS already has a lot of preclinical data in many cancer indications, but they plan to generate new additional data in monotherapy against unmet medical needs and in combination with promising drugs from other pharmaceutical companies. Frederic CAROFF, Florian Denis, Martine Caroff, Alexey Novikov Read more - https://lnkd.in/gYkPH4mH To share your startup story write us on - contact@startuprise.co.uk #HEPHAISTOSPharma #biotechstartup #revolutionizing #monotherapy #pharmaceutical #funding #fundingnews #news #startup #startupnews #startuprise

10 Noteworthy Global Biotech Companies that Got Funded in the first Quarter of 2024 According to data sourced from Crunchbase, the funding for Biotech companies represents a 161 percent upsurge compared to the USD 1.1 billion raised by the largest funding rounds which involved healthcare-focused biotech companies in the first quarter of 2023. Read the full article: https://goo.su/HCqWR By Samrat Pradhan, Managing Editor, #FinanceOutlookIndia Zephyr AI Yiyuan Yin FogPharma Mike Nolan Andrew Chi Baiteng Zhao Tubulis GmbH Laura Shawver Rakuten Medical Clasp Therapeutics Greg Chow, Freenome Diagonal Therapeutics Jixing Pharmaceuticals Obsidian Therapeutics Alamar Biosciences, Inc. ARS Pharmaceuticals, Inc. Nadia Agopyan, Ph.D., RAC Mark M, Sionna Therapeutics BlossomHill Therapeutics, Inc. BJ Sullivan, PhD, BioAge Labs Catherine Priest, Neurona Therapeutics #GlobalBiotech #FirstQuarter2024 #Biotechnologyindustry #FundingRounds #EmergingBiotechFirms #VentureCapital #TechnologicalAdvances #InnovationSpotlight

Alumis, an 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 on the cusp of 𝐏𝐡𝐚𝐬𝐞 𝟑, has secured $𝟐𝟓𝟎𝐌 𝐢𝐧 𝐚 𝐬𝐡𝐫𝐮𝐧𝐤𝐞𝐧 𝐈𝐏𝐎. The Bay Area startup sold 𝟏𝟑.𝟏𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 𝐚𝐭 $𝟏𝟔 𝐞𝐚𝐜𝐡 to fund the late-stage testing of its lead 𝐓𝐘𝐊𝟐 𝐝𝐫𝐮𝐠, studies of a second asset in neuroinflammatory conditions, and preclinical projects. While the IPO was smaller than initially projected, an additional 𝟐.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 were sold in a concurrent private placement. With $𝟑𝟒𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐥𝐥𝐨𝐜𝐚𝐭𝐞𝐝 toward clinical development, Alumis aims to create a next-gen immunology treatment, facing competition from Bristol Myers Squibb’s Sotyktu and Takeda’s TAK-279. Alumis has spent heavily on R&D, with $𝟏𝟑𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫 𝐚𝐧𝐝 $𝟏𝟎𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐. The company, led by Martin Babler, hopes to buck the trend of biotechs trading below their IPO price. https://lnkd.in/eK_H6kda #Biotech #Immunology #IPO #Pharma #HealthcareInnovation

𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The research report encompasses an overview of the development of the Cancer Janus Kinase Inhibitors industry chain, focusing on its applications in Hospitals (Ruxolitinib, Momelotinib) and Ambulatory Surgical Centers (Ruxolitinib, Momelotinib). It highlights key enterprises in both developed and developing markets while analyzing cutting-edge technology, patents, hot applications, and market trends of Cancer Janus Kinase Inhibitors. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/guSqh8-w *𝗕𝘆 𝗧𝘆𝗽𝗲: Ruxolitinib, Momelotinib, Lestaurtinib, Pacritinib, *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Ambulatory Surgical Centers, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Abbott, Asana BioSciences, LLC, AstraZeneca, Celonic Group, Dynamic Pharma S.A. – Δυναμική Φαρμακαποθήκη Α.Ε., Eli Lilly and Company, Gilead Sciences, Hanmi Pharmaceuticals, Incyte, Kyowa Hakko USA, Moleculin Biotech, Inc., Pfizer, Portola Pharmaceuticals #januskinaseinhibitors #cancerresearch #cancertreatment #oncology #drugdevelopment #cancertherapeutics #pharmaceuticals #biomedicalscience #jakinhibitors #precisionmedicine

Stories making headlines today in the biopharma industry: Merck's CMO, Eliav Barr, has declared the organization's intention to magnify its immunology pipeline through further deals, specifically focusing on cardiometabolic drugs and immunology. In other news, GSK has pledged to purchase Aiolos Bio, a clinical-stage asthma drugmaker, for a hefty $1.4 billion. This development has facilitated one of the swiftest startup reveal-to-acquisition journeys in biotech history, as Aiolos Bio was only unveiled three months ago, bolstered by the backing of a number of renowned investors. Meanwhile, rumors indicating a possible acquisition of the biotechnology company Cytokinetics by Novartis have been downplayed by the latter's CEO, Vas Narasimhan. In an interview with CNBC, he emphasized Novartis' focus on smaller, "$5 billion or less" assets, debunking the alleged buyout speculation. On another note, radiopharma firm Lantheus has initiated collaboration with Perspective Therapeutics, investing $28M upfront to secure an exclusive licensing deal directed towards an alpha-targeted therapy for neuroendocrine tumors. This move is set to extend its hand even further in the radiopharma sphere and solidify its presence in this field. #pharma #biotech #topstories #biodatastudio

Interesting set of questions and discussion on life sciences. I think there is a lot of debate on the low success rate and do preclinical data/models translate well. In oncology, at least, I actually think they do so well if you are really careful in mapping PK-PD-efficacy relationships from in vitro to in vivo to tox models and the Ph1 data. If there was only 50% TGI, as lots of drugs show, that actually isn't good prognosis for clinical monotherapy. The model hasn't failed if the human data fails to show RECIST response in humans. Also, the models are frequently selected for a best case subset which an all comers advanced does not really represent. https://lnkd.in/eSSeSs9a

Aragen is thrilled to participate in the 8th Annual IPF Summit in Boston, MA, on August 21-22, 2024, at booth no. 2. Aragen offers a comprehensive portfolio of in vivo, in vitro, and ex vivo fibrosis models, paired with world-class expertise in anti-fibrotic therapeutic development. Over the past decade, we've evaluated the efficacy of test compounds across various modalities—small molecules, biologics, RNA therapeutics, exosomes, and more—leading to successful IND submissions. Our specialized diet-induced, chemical-induced, and surgical fibrosis models and thorough disease parameter evaluations are crucial in advancing novel therapies. Notably, our bleomycin-induced pulmonary fibrosis (IPF) model is highly reproducible and has been instrumental in accelerating drug candidates beyond the preclinical phase, supporting both therapeutic and prophylactic developments. Click here https://lnkd.in/gFff_EP6 to schedule a meeting, today with our experts! Danielle Liu & Malavika Ghosh #vivo #invitro #exvivo #fibrosismodels #pulmonaryfibrosis #biologics #drugdevelopment #INDfiling #events2024 #CDMO #CRO #lifesciences #endtoendsolutions #therapeutics

Stories making headlines today in the biopharma industry: Acorda Therapeutics, a renowned biotech company, has declared bankruptcy amidst legal and financial difficulties since 2017. The company has decided to sell off its assets, including a proprietary Multiple Sclerosis drug, to Merz Therapeutics for a sum of $185 million. In other sector news, Roivant has shared uplifting results from their Phase 2 eye disease drug trial, conducted in partnership with pharmaceutical giant Pfizer. Capitalizing on this success, Roivant is launching an unprecedented $1.5 billion share buyback program. However, contrasting fortunes struck Gritstone as its Phase 2 study for a novel cancer vaccine delivered mixed results, leading to a significant drop in its stock value. Despite the recent upset, Gritstone remains optimistic and is committed to moving forward with public stock offerings and advanced Phase 3 trials. Meanwhile, Praia Health, a healthcare startup pioneering in improving patient engagement with healthcare systems, managed to secure $20 million in a recent Series A funding round. The promising venture seeks to leverage this substantial capital influx to develop groundbreaking products that seamlessly connect consumers with vital healthcare services. In the corporate world, Zymeworks revealed the removal of CFO Christopher Astle, with CEO Kenneth Galbraith set to fill the position on a temporary basis. Concurrently, Gilead confirmed the expansion of its existing deal with Nurix. Lastly, Verve Therapeutics has decided to hit pause on its leading gene editing program following an adverse safety event. In its pursuit of safety and proficiency, the firm plans to shift gears towards a similar program that employs a different type of lipid delivery mechanism. #pharma #biotech #topstories #biodatastudio

Another name to add to the AI in drug discovery watchlist: Xaira Therapeutics. The headlines rightly focus on the big (ok, really big - $1 billion) money and names behind this new "powerhouse". As yet, I can't find any solid details on its therapeutic areas or targets of interest, only that it plans to advance unspecified “multiple” drug programs. However, the company is advertising for a Head of Immunology and Inflammatory Diseases and a Head of Oncology. The source of its training data is also unclear at this stage. These are exciting times in the AI in drug discovery field with publication of preclinical and clinical models of INS018_055, a small-molecule TNIK inhibitor developed by by Insilico Medicine (https://lnkd.in/exdPgPND). The candidate has moved into Phase II trials. Exscientia is also making progress in the clinic with a CDK7 inhibitor currently in a Phase 1/2 clinical trial. The company anticipates initiating a Phase 1 patient study this year for its LSD1 inhibitor and continuing to progress its MALT1 inhibitor through IND-enabling studies this year. It certainly feels like the future of drug discovery is here. #drugdiscovery #AI #pharma https://lnkd.in/eci7ZcGk